These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 23397499)

  • 1. Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
    Machiels JP; Kaminsky MC; Keller U; Brümmendorf TH; Goddemeier T; Forssmann U; Delord JP
    Invest New Drugs; 2013 Oct; 31(5):1207-16. PubMed ID: 23397499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).
    Vermorken JB; Peyrade F; Krauss J; Mesía R; Remenar E; Gauler TC; Keilholz U; Delord JP; Schafhausen P; Erfán J; Brümmendorf TH; Iglesias L; Bethe U; Hicking C; Clement PM
    Ann Oncol; 2014 Mar; 25(3):682-688. PubMed ID: 24567516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
    Jimeno A; Machiels JP; Wirth L; Specenier P; Seiwert TY; Mardjuadi F; Wang X; Kapp AV; Royer-Joo S; Penuel E; McCall B; Pirzkall A; Clement PM
    Cancer; 2016 Dec; 122(24):3803-3811. PubMed ID: 27525588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease.
    Chan E; Kwak EL; Hwang J; Heiskala M; de La Bourdonnaye G; Mita M
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):701-9. PubMed ID: 25627002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: results of a phase II trial.
    Yoshino T; Hasegawa Y; Takahashi S; Monden N; Homma A; Okami K; Onozawa Y; Fujii M; Taguchi T; de Blas B; Beier F; Tahara M
    Jpn J Clin Oncol; 2013 May; 43(5):524-31. PubMed ID: 23479384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.
    Chow LQM; Morishima C; Eaton KD; Baik CS; Goulart BH; Anderson LN; Manjarrez KL; Dietsch GN; Bryan JK; Hershberg RM; Disis ML; Martins RG
    Clin Cancer Res; 2017 May; 23(10):2442-2450. PubMed ID: 27810904
    [No Abstract]   [Full Text] [Related]  

  • 7. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
    Guigay J; Aupérin A; Fayette J; Saada-Bouzid E; Lafond C; Taberna M; Geoffrois L; Martin L; Capitain O; Cupissol D; Castanie H; Vansteene D; Schafhausen P; Johnson A; Even C; Sire C; Duplomb S; Evrard C; Delord JP; Laguerre B; Zanetta S; Chevassus-Clément C; Fraslin A; Louat F; Sinigaglia L; Keilholz U; Bourhis J; Mesia R; ; ;
    Lancet Oncol; 2021 Apr; 22(4):463-475. PubMed ID: 33684370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck.
    Saba NF; Hurwitz SJ; Magliocca K; Kim S; Owonikoko TK; Harvey D; Ramalingam SS; Chen Z; Rogerio J; Mendel J; Kono SA; Lewis C; Chen AY; Higgins K; El-Deiry M; Wadsworth T; Beitler JJ; Shin DM; Sun SY; Khuri FR
    Cancer; 2014 Dec; 120(24):3940-51. PubMed ID: 25103371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer.
    Cohen MH; Chen H; Shord S; Fuchs C; He K; Zhao H; Sickafuse S; Keegan P; Pazdur R
    Oncologist; 2013; 18(4):460-6. PubMed ID: 23576486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy.
    Smith DA; Conkling P; Richards DA; Nemunaitis JJ; Boyd TE; Mita AC; de La Bourdonnaye G; Wages D; Bexon AS
    Cancer Immunol Immunother; 2014 Aug; 63(8):787-96. PubMed ID: 24770667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part.
    Vermorken JB; Guigay J; Mesia R; Trigo JM; Keilholz U; Kerber A; Bethe U; Picard M; Brummendorf TH
    Br J Cancer; 2011 May; 104(11):1691-6. PubMed ID: 21540865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of cabazitaxel in combination with platinum and 5-fluorouracil (PF) in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN).
    Camille N; Rozehnal J; Roy E; Uczkowski D; Olson A; Genden E; Teng M; Bakst R; Gupta V; Posner M; Misiukiewicz K
    Oral Oncol; 2017 Aug; 71():99-104. PubMed ID: 28688700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction chemotherapy with docetaxel, cisplatin and capecitabine, followed by combined cetuximab and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck: a phase I-II study.
    Perri F; Muto P; Argenone A; Ionna F; Longo F; Fulciniti F; Sandomenico F; Daponte A; Caponigro F
    Oncology; 2013; 84(4):251-4. PubMed ID: 23428719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution.
    de Mello RA; Gerós S; Alves MP; Moreira F; Avezedo I; Dinis J
    PLoS One; 2014; 9(2):e86697. PubMed ID: 24516537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
    Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
    BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platinum-based chemotherapy plus cetuximab in head and neck cancer.
    Vermorken JB; Mesia R; Rivera F; Remenar E; Kawecki A; Rottey S; Erfan J; Zabolotnyy D; Kienzer HR; Cupissol D; Peyrade F; Benasso M; Vynnychenko I; De Raucourt D; Bokemeyer C; Schueler A; Amellal N; Hitt R
    N Engl J Med; 2008 Sep; 359(11):1116-27. PubMed ID: 18784101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck.
    Kuhnt T; Sandner A; Wendt T; Engenhart-Cabillic R; Lammering G; Flentje M; Grabenbauer G; Schreiber A; Pirnasch A; Dunst J
    Ann Oncol; 2010 Nov; 21(11):2284-2289. PubMed ID: 20427347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen.
    Soulières D; Aguilar JL; Chen E; Misiukiewicz K; Ernst S; Lee HJ; Bryant K; He S; Obasaju CK; Chang SC; Chin S; Adkins D
    BMC Cancer; 2016 Jan; 16():19. PubMed ID: 26768732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Vermorken JB; Licitra L; Stöhlmacher-Williams J; Dietz A; Lopez-Picazo JM; Hamid O; Hossain AM; Chang SC; Gauler TC
    Eur J Cancer; 2013 Sep; 49(13):2877-83. PubMed ID: 23726971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study.
    Guigay J; Fayette J; Dillies AF; Sire C; Kerger JN; Tennevet I; Machiels JP; Zanetta S; Pointreau Y; Bozec Le Moal L; Henry S; Schilf A; Bourhis J
    Ann Oncol; 2015 Sep; 26(9):1941-1947. PubMed ID: 26109631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.